Table 1.
Author | Vaccine | Country of origin | Sample size | Mean/median age | Immunoglobulin measurement | Serial/nonserial serologic measurement | Reported values | % Difference from peak |
---|---|---|---|---|---|---|---|---|
Campo et al 10 | Pfizer‐BioNTech | Italy | Healthcare workers: 274 | Median (range) | Diasorin, LIAISON, IgG, S1/S2 | Serial | Geometric means and 95% confidence Intervals | D28 |
There is 9% decrease 21 days after the peak rise of IgG titer on Day 7 after full vaccinationD61There is 41% decrease 54 days after the peak rise of IgG titer on Day 7 after full vaccination | ||||||||
Male: 99 | 46.1 years | D147 | ||||||
Female: 175 | (23–69 years) | There is 55% decrease 140 days after the peak rise of IgG titer on Day 7 after full vaccination | ||||||
Salvagno et al. 12 | Pfizer‐BioNTech | Italy | Healthcare workers: 787 | Mean age: 44 ± 12 years | Roche, Elecsys, total Ig, RBD | Serial | Medians and interquartile ranges | D90 |
<65 years: 754 | There is 38% decrease 60 days after the peak rise of IgG titer on Day 30 after full vaccination | |||||||
≥65 years: 33 | D180 | |||||||
Male: 268 | There is 55% decrease 150 days after the peak rise of IgG titer on Day 30 after full vaccination | |||||||
Female: 519 | ||||||||
Ponticelli et al. 17 | Pfizer‐BioNTech | Italy | Healthcare workers: 162 | Mean age: 42.5 ± 11.9 years | SNIBE, MAGLUMI, IgG, RBD | Serial | Medians and interquartile ranges | D180 |
Male: 68 | ||||||||
Female: 94 | There is 90% decrease 150 days after the peak rise of IgG titer on Day 30 after full vaccination | |||||||
Salvagno et al. 18 | Pfizer‐BioNTech | Italy | Baseline SARS‐CoV‐2 | Median age: 42 years | Euroimmun, IgA, spike S1 subunit | Serial | Medians and interquartile ranges | D180 |
Seronegative | ||||||||
Healthcare workers: 97 | IQR: 31–52 years | There is 71% decrease 150 days after the peak rise of IgA titer on Day 30 after full vaccination | ||||||
Kato et al. 19 | Pfizer‐BioNTech | Japan | Healthcare workers: 98 | Median age: 43 years | Tosoh, AIA‐CL, IgG, nucleocapsid/spike | Serial | Geometric means and 95% confidence intervals | D201 |
Male: 24 | IQR: 38–49 years | |||||||
Female: 74 | There is 93% decrease 180 days after the peak rise of IgG titer on Day 21 after full vaccination | |||||||
Naaber et al. 20 | Pfizer‐BioNTech | Estonia | Laboratory employees: 122 | Median age: 34 years | Abbott, IgG, RBD | Serial | Medians and interquartile ranges | D42 |
There is 48% decrease 35 days after the peak rise of IgG titer on Day 7 after full vaccination | ||||||||
D84 | ||||||||
There is 79% decrease 87 days after the peak rise of IgG titer on Day 7 after full vaccination | ||||||||
Male: 21 | Range: 21–69 years | D180 | ||||||
Female: 101 | There is 94% decrease 161 days after the peak rise of IgG titer on Day 7 after full vaccination | |||||||
Laing et al. 21 | Pfizer‐BioNTech | USA | Healthcare workers: 187 | Mean age: 42.8 years | LakePharma, Multiplex microsphere‐based immunoassay, IgG, nucleocapsid/spike | Serial | Geometric meansand 95% confidence intervals | D180 |
Male: 56 | IQR: 21–69 years | |||||||
Female: 131 | There is 77% decrease 150 days after the peak rise of IgG titer on Day 30 after full vaccination | |||||||
Israel et al. 22 | Pfizer‐BioNTech | Israel | 2653 | Mean age: 56.45 ± 15.87 years | Abbott, Alinity i, IgG, RBD | Nonserial | Medians and interquartile ranges | D30–59 |
There is 48% decrease 30 days after the peak rise of total antibody titer on Days 0–29 after full vaccination | ||||||||
D60–89 | ||||||||
There is 78% decrease 60 days after the peak rise of total antibody titer on Days 0–29 after full vaccination | ||||||||
D90–119 | ||||||||
There is 87% decrease 90 days after the peak rise of total antibody titer on Days 0–29 after full vaccination | ||||||||
D120–149 | ||||||||
There is 89% decrease 120 days after the peak rise of total antibody titer on Days 0–29 after full vaccination | ||||||||
D150–179 | ||||||||
There is 92% decrease 150 days after the peak rise of total antibody titer on Days 0–29 after full vaccination | ||||||||
D180+ | ||||||||
There is 95% decrease 180 days after the peak rise of total antibody titer on Days 0–29 after full vaccination | ||||||||
Kertes et al. 23 | Pfizer‐BioNTech | Israel | 8395 | No data | Abbott, Quant II,IgG, RBD | Nonserial | Means and 95% confidence intervals | D30–59 |
There is 42% decrease 30 days after the peak rise of total antibody titer on Days 7–29 after full vaccination | ||||||||
D60–89 | ||||||||
There is 78% decrease 60 days after the peak rise of total antibody titer on Days 7–29 after full vaccination | ||||||||
D90–119 | ||||||||
There is 87% decrease 90 days after the peak rise of total antibody titer on Days 7–29 after full vaccination | ||||||||
D120–149 | ||||||||
There is 89% decrease 120 days after the peak rise of total antibody titer on Days 7–29 after full vaccination | ||||||||
D150–179 | ||||||||
There is 92% decrease 150 days after the peak rise of total antibody titer on Days 7–29 after full vaccination | ||||||||
D 180+ | ||||||||
There is 95% decrease 180 days after the peak rise of total antibody titer on Days 7–29 after full vaccination | ||||||||
Salvagno et al. 24 | Pfizer‐BioNTech | Italy | 86 | Median age: 45 years | DiaSorin, LIAISON, IgG, spike trimeric | Serial | Medians and interquartile ranges | D180 |
IQR: 31–53 years | New Industries Biomedical Engineering Co., LTD, MAGLUMI, IgG, RBD | There is 83% and 92% decrease 150 days afterthe peak rise of anti‐spike trimeric IgG and RBD IgG titers, respectively, on Day 30 after full vaccination | ||||||
Khoury et al. 25 | Pfizer‐BioNTech | Israel | Healthcare workers: 100 | Mean age: | Abbot's © quant assay, IgG, RBD | Serial | Medians | D60 |
and ranges | There is 56% decrease 30 days after the peak rise of total antibody titer on Day 30 after full vaccination | |||||||
D90 | ||||||||
Male: 55 | ||||||||
Female: 45 | There is 88% decrease 60 days after the peak rise of total antibody titer on Day 30 after full vaccination | |||||||
40.7 ± 13.7 years | ||||||||
D120 | ||||||||
There is 94% decrease 90 days after the peak rise of total antibody titer on Day 30 after full vaccination | ||||||||
Ciabattini et al. 26 | Pfizer‐BioNTech | Italy | 145 | Mean age: 48.8 ± 14.3 years | In‐house ELISA, IgG, S1/S2 | Nonserial | Geometric means and 95% confidence Intervals | D97 |
There is 65% decrease 90 days after the peak rise of anti‐spike IgG titer on Day 7 after full vaccination | ||||||||
D167 | ||||||||
There is 85% decrease 160 days after the peak rise of anti‐spike IgG titer on Day 7 after full vaccination | ||||||||
Brisotto et al. 27 | Pfizer‐BioNTech & Moderna | Italy | 516 | Median age: 46.5 years | SNIBE, MAGLUMI, IgG, RBD | Serial | Medians and interquartile ranges | D20 |
Male: 145 | IQR: 36–55 years | |||||||
Female: 371 | There is 83% decrease 90 days after the peak rise of IgG titer on Day 30 after full vaccination |
Abbreviations: IgG, immunoglobulin G; mRNA, messenger RNA; RBD, receptor‐binding domain; SARS‐CoV‐2, severe acute respiratory syndrome coronavirus 2.